Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology · Bioinfo & AI

Multi-Omics Integration Identifies a Five-Gene Metabolic Signature With Experimental Validation in Clear Cell Renal Cell Carcinoma

Summary

This study employed a multi-omics approach to decipher the metabolic-immune interplay in clear cell renal cell carcinoma (ccRCC). Researchers identified a five-gene metabolic signature (SUCLA2, ACAT1, PC, SUCLG1, HMGCS2) that predicts prognosis with superior accuracy compared to conventional clinical staging. This signature is associated with distinct tumor immune microenvironment states and enables patient stratification for personalized therapeutic strategies. In vitro experimental validations confirmed SUCLA2's role as a potential tumor suppressor, designating it as a promising target.

Critical appraisal

Clinical. This study establishes a precision oncology framework for ccRCC, presenting a five-gene metabolic signature with superior prognostic value compared to current clinical markers. The identification of LY2109761 and carmustine as candidate agents specific to high-risk patients paves the way for early-phase clinical trials (I/II) to validate these targeted therapies. The identified biomarker is prognostic and could justify changes in risk stratification and therapeutic decision-making, with a potential clinical impact within 3-5 years following further validation.

Molecular biology. Multi-omics integration (transcriptomic, genomic) led to the discovery of a five-gene metabolic signature (SUCLA2, ACAT1, PC, SUCLG1, HMGCS2) involved in lipid metabolism and hypoxia response. Functional validation of SUCLA2 through in vitro gain- and loss-of-function assays, alongside expression analyses (TCGA, HPA, western blot, qRT-PCR), corroborates its tumor-suppressive role. This discovery provides a promising molecular target for the development of novel therapeutic and diagnostic strategies, with clear translational implications for clinical tests based on SUCLA2 expression.

Bioinfo & AI. The study developed a machine learning-based prognostic framework, utilizing SHAP for feature interpretability, which is a robust approach for identifying key genes. Deconvolution algorithms were employed to dissect tumor immune microenvironment heterogeneity, and the integration of TMB and TIDE scores allowed for the characterization of immune evasion. While open-source code is not explicitly mentioned, the use of interpretable methods and multi-omics data enhances the model’s reproducibility and robustness, potentially deployable to refine patient stratification in clinical workflows.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology